| Biological Sciences | Lifetime | 18 | US 11 | 100.00 |
| Biological Sciences | 2021-2025 | 687 | US 152 | 99.27 |
| Molecular Biology | Lifetime | 1 | US 1 | 100.00 |
| Cancer Research | Lifetime | 112 | US 64 | 99.41 |
| Genetics | Lifetime | 516 | US 274 | 98.80 |
| Cell Biology | Lifetime | 328 | US 190 | 98.42 |
| Cardiology and Cardiovascular Medicine | Lifetime | 662 | US 348 | 98.83 |
| Molecular Biology | 2021-2025 | 184 | US 49 | 99.25 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 634 | US 271 | 88.96 |
| Ubiquitin and proteasome pathways | Lifetime | 1 | US 1 | 99.97 |
| Muscle Physiology and Disorders | Lifetime | 1 | US 1 | 100.00 |
| Congenital heart defects research | Lifetime | 1 | US 1 | 99.99 |
| Histone Deacetylase Inhibitors Research | Lifetime | 1 | US 1 | 99.98 |
| Signaling Pathways in Disease | Lifetime | 1 | US 1 | 99.99 |
| RNA Research and Splicing | Lifetime | 4 | US 3 | 99.95 |
| Cardiac Fibrosis and Remodeling | Lifetime | 1 | US 1 | 99.93 |
| Circular RNAs in diseases | Lifetime | 3 | US 2 | 99.93 |
| MicroRNA in disease regulation | Lifetime | 7 | US 4 | 99.93 |
| Cardiomyopathy and Myosin Studies | Lifetime | 11 | US 7 | 99.86 |
| Peptidase Inhibition and Analysis | Lifetime | 30 | US 19 | 99.81 |
| RNA modifications and cancer | Lifetime | 54 | US 35 | 99.80 |
| CRISPR and Genetic Engineering | Lifetime | 55 | US 43 | 99.69 |
| Cancer-related molecular mechanisms research | Lifetime | 102 | US 40 | 99.46 |
| Genetics and Neurodevelopmental Disorders | Lifetime | 51 | US 28 | 99.62 |
| Tissue Engineering and Regenerative Medicine | Lifetime | 47 | US 26 | 99.63 |
| Pluripotent Stem Cells Research | Lifetime | 85 | US 47 | 99.28 |
| Neurogenetic and Muscular Disorders Research | Lifetime | 72 | US 30 | 99.06 |
| Cancer-related gene regulation | Lifetime | 166 | US 89 | 98.87 |
| Developmental Biology and Gene Regulation | Lifetime | 48 | US 31 | 99.25 |
| Congenital Heart Disease Studies | Lifetime | 285 | US 163 | 98.72 |
| Protein Degradation and Inhibitors | Lifetime | 160 | US 96 | 98.66 |
| Nuclear Receptors and Signaling | Lifetime | 77 | US 43 | 98.69 |
| Hippo pathway signaling and YAP/TAZ | Lifetime | 78 | US 41 | 97.81 |
| Adipose Tissue and Metabolism | Lifetime | 655 | US 303 | 98.41 |
| Epigenetics and DNA Methylation | Lifetime | 844 | US 441 | 98.11 |
| Cardiac Structural Anomalies and Repair | Lifetime | 660 | US 393 | 98.17 |
| Virus-based gene therapy research | Lifetime | 997 | US 586 | 97.50 |
| Genomics and Chromatin Dynamics | Lifetime | 660 | US 380 | 97.30 |
| Animal Genetics and Reproduction | Lifetime | 573 | US 274 | 96.42 |
| Viral Infections and Immunology Research | Lifetime | 986 | US 405 | 95.78 |
| Protein Kinase Regulation and GTPase Signaling | Lifetime | 556 | US 289 | 96.43 |
| Wnt/β-catenin signaling in development and cancer | Lifetime | 629 | US 264 | 94.03 |
| Biotin and Related Studies | Lifetime | 340 | US 182 | 93.13 |
| Genetics, Aging, and Longevity in Model Organisms | Lifetime | 687 | US 373 | 94.03 |
| Kruppel-like factors research | Lifetime | 515 | US 194 | 91.49 |
| Genetics and Physical Performance | Lifetime | 656 | US 189 | 83.13 |
| Congenital limb and hand anomalies | Lifetime | 522 | US 217 | 84.13 |
| CRISPR and Genetic Engineering | 2021-2025 | 16 | US 7 | 99.15 |
| Muscle Physiology and Disorders | 2021-2025 | 15 | US 5 | 98.80 |
| Virus-based gene therapy research | 2021-2025 | 38 | US 20 | 97.96 |
| Congenital heart defects research | 2021-2025 | 39 | US 20 | 95.29 |
| Viral Infections and Immunology Research | 2021-2025 | 78 | US 28 | 95.54 |
| Pluripotent Stem Cells Research | 2021-2025 | 65 | US 19 | 95.60 |
| RNA Research and Splicing | 2021-2025 | 706 | US 233 | 89.30 |
| Cardiomyopathy and Myosin Studies | 2021-2025 | 501 | US 176 | 89.53 |
| Nuclear Structure and Function | 2021-2025 | 277 | US 110 | 72.66 |
